Prothena Corp (PRTA) to Benefit from Increased Alzheimer Attention - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $38.00 price target on Prothena Corp (NASDAQ: PRTA) after the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
